SCHEMBL6804052

SCHEMBL6804052

CC(=O)Oc1cc(C)ccc1C1CCN(CCCCNC(=O)c2ccc(NC(=O)c3ccc(Cl)cc3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.50
TMEM97 Q5BJF2 1/20 0.46
MCHR1 Q99705 1/20 0.46
DRD2 P14416 7/20 0.44
DRD3 P35462 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
NPC1 O15118 1/20 0.44
F2 P00734 1/20 0.44
RAB9A P51151 1/20 0.44
DRD4 P21917 6/20 0.44
DRD1 P21728 1/20 0.44
CCR2 P41597 1/20 0.43
EPHX2 P34913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805753 0.91 SLC2A1 (0.49) SLC2A1MCHR1DRD2DRD3MAPT
SCHEMBL3117879 0.90 SLC2A1 (0.50) SLC2A1TMEM97MCHR1DRD2DRD3
SCHEMBL6712456 0.88 SLC2A1 (0.48) SLC2A1TMEM97MCHR1DRD2DRD3
SCHEMBL6807063 0.88 SLC2A1 (0.48) SLC2A1TMEM97MCHR1DRD2DRD3
SCHEMBL3120471 0.88 SLC2A1 (0.48) SLC2A1TMEM97MCHR1DRD2DRD3
SCHEMBL3120464 0.88 SLC2A1 (0.48) SLC2A1TMEM97MCHR1DRD2DRD3
SCHEMBL3120459 0.87 SLC2A1 (0.47) SLC2A1TMEM97MCHR1DRD2DRD3
SCHEMBL6807067 0.84 SLC2A1 (0.44) SLC2A1TMEM97MCHR1DRD2DRD3
SCHEMBL3117184 0.84 DRD2 (0.54) SLC2A1DRD2DRD3DRD4DRD1
SCHEMBL3121723 0.83 DRD2 (0.51) SLC2A1MCHR1DRD2DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072865-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression SMITHKLINE BEECHAM CORPORATION 2004-04-15 US claimed
EP-1351935-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 EP claimed
WO-2002055495-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 WO claimed
US-20040072865-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression SMITHKLINE BEECHAM CORPORATION 2004-04-15 US disclosed
EP-1351935-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 EP disclosed
WO-2002055495-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072865-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression NR1H2, NR1H3, NR1H4 SLC2A1 345/4885TMEM97 147/4885MCHR1 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.